Long acting GLP-1 receptor agonist (injectable)
Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
LIRA_SC_FLEX_QD
Sensitivity analysis assigns the arm to 1.8 mg. A flexible regimen with a different permitted dose set or algorithm is a different node.
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Insulin aspart (prandial) | HR 0.49 (0.16 to 1.67) | 0.72 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.59 (-1.83 to 3.17) | 0.42 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.56 (0.18 to 1.60) | 0.71 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD 0.40 (-0.47 to 1.24) | 0.13 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD 0.37 (-0.59 to 1.36) | 0.20 |
Trials
- NCT02953665A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease2017 · 63 randomized · 54 weeks
- NCT03151005Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients2017 · 70 randomized · 12 weeks
- TODINELIA Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.2014 · 48 randomized · 26 weeks
- SIMPLEThe Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study2014 · 120 randomized · 26 weeks